MedTrace Logo

Study to Evaluate the Relative Abuse Potential of Almorexant in Recreational Drug Users

NCT01987739 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2016-02-12

No results posted yet for this study

Summary

This was a six-way crossover study with six single-dose treatment sessions. The profile of acute effects on abuse potential measures of different almorexant doses was compared to that of placebo and two doses of zolpidem

Conditions

  • Abuse Potential Study

Interventions

DRUG

200 mg almorexant

DRUG

400 mg almorexant

DRUG

1000 mg almorexant

DRUG

20 mg zolpidem

DRUG

40 mg zolpidem

DRUG

placebo

Sponsors & Collaborators

  • Midnight Pharma, LLC

    lead INDUSTRY

Principal Investigators

  • Edward M Sellers, MD, PhD · Kendle Early Stage - Toronto

Study Design

Allocation
RANDOMIZED
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-02-28
Completion
2010-02-28

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01987739 on ClinicalTrials.gov